Sangamo Biosciences files $50 million stock, warrant shelf

By Angela McDaniels

Seattle, May 26 - Sangamo Biosciences Inc. registered to sell up to $50 million of securities in an S-3 filing with the Securities and Exchange Commission.

Covered by the shelf are shares of common stock and warrants.

The shelf includes part of a previous $9,442,000.24 registration that was unsold and is carried forward.

Proceeds will be used for general corporate purposes, including research and development, commercialization and business development activities and, if opportunities arise, acquisitions of businesses, products or licenses.

Sangamo is based in Richmond, Calif., and develops novel DNA-binding proteins for therapeutic gene regulation and modification to treat patients with diabetic neuropathy and peripheral artery disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.